Morgan Stanley Initiates Cidara Therapeutics (CDTX) With a Buy

Group 1 - Cidara Therapeutics, Inc. (NASDAQ:CDTX) is recognized as a promising growth stock, with a Buy rating initiated by Morgan Stanley and a price target of $190 [1] - The lead candidate, CD388, is highlighted as a significant factor for the positive outlook, positioned to play a major role in the influenza prophylaxis market due to its single-dose prevention capability [2] - Important phase 3 interim results for CD388 are anticipated in June 2026, with expectations of demonstrating season-long durability and broad protection [2] Group 2 - CD388 has received Fast Track and Breakthrough Therapy designations, indicating its potential for expedited development [3] - The total addressable market for CD388 is estimated to exceed $5 billion, presenting a substantial market opportunity for Cidara Therapeutics [3] - Cidara Therapeutics utilizes its Cloudbreak platform to develop drug-Fc conjugates aimed at targeting diseases and activating the immune system [3]